Eupraxia Pharmaceuticals Inc.

Contributing Author

Recent Articles by Eupraxia Pharmaceuticals Inc.

Jul-08	Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis EPRX GlobeNewswire
Jun-02	Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders EPRX GlobeNewswire
May-07	Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 EPRX GlobeNewswire
May-06	Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results EPRX GlobeNewswire
May-05	Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI EPRX GlobeNewswire